Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer

Published:October 22, 2022DOI:


      • Endometrial cancer is difficult to treat beyond the established frontline regimen of carboplatin and paclitaxel
      • Platinum rechallenge is often considered at the time of recurrence because of the lack of effective treatment options
      • Molecular characterization of endometrial cancer provided the rationale for immunotherapies and targeted therapy options
      • Molecular phenotype should be considered to guide best treatment practices and in clinical trials for endometrial cancer


      Endometrial cancer incidence and mortality are rising among all ethnic groups. Carboplatin plus paclitaxel is the established frontline treatment for advanced/recurrent disease; however, subsequent treatment with traditional cytotoxic chemotherapy is challenging. The molecular characterization of endometrial cancer has provided important insights into the biological drivers of carcinogenesis, which has allowed for the development of newer precision immunotherapies and targeted therapies, including pembrolizumab, dostarlimab, and lenvatinib. Until recently, platinum rechallenge was often considered at the time of recurrence, given the lack of other available therapeutic options; however, “platinum sensitivity” in endometrial cancer is subjective and largely based on expert opinion and/or practitioner experience. Small retrospective studies have tried to provide guidance on the utility of platinum rechallenge, but they are limited by variable patient characteristics and small sample sizes. The applicability of these retrospective studies to contemporary clinical practice is difficult in the setting of changing patient demographics, a better understanding of endometrial cancer drivers, and the recent approvals of immune checkpoint inhibitors and the combination of lenvatinib plus pembrolizumab in the second-line setting. The primary focus of this review is to distill the available data regarding platinum-doublet chemotherapy rechallenge and highlight recent pivotal developments in endometrial cancer treatment, as well as future directions.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Sung H.
        • et al.
        Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
        CA Cancer J. Clin. 2021; 71: 209-249
        • Henley S.J.
        • et al.
        Annual report to the nation on the status of cancer, part I: national cancer statistics.
        Cancer. 2020; 126: 2225-2249
        • Lauby-Secretan B.
        • et al.
        Body fatness and Cancer — viewpoint of the IARC working group.
        N. Engl. J. Med. 2016; 375: 794-798
        • Onstad M.A.
        • Schmandt R.E.
        • Lu K.H.
        Addressing the role of obesity in endometrial Cancer risk, prevention, and treatment.
        Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016; 34: 4225-4230
        • Cote M.L.
        • et al.
        The growing burden of endometrial Cancer: a major racial disparity affecting black women.
        Cancer Epidemiol. Biomark. Prev. 2015; 24: 1407-1415
        • Evans T.
        • et al.
        Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006.
        Br. J. Cancer. 2011; 104: 1505-1510
        • Pandita P.
        • et al.
        Unique molecular features in high-risk histology endometrial cancers.
        Cancers (Basel). 2019; 11
        • Huijgens A.N.
        • Mertens H.J.
        Factors predicting recurrent endometrial cancer.
        Facts Views Vis Obgyn. 2013; 5: 179-186
        • Siegel R.L.
        • et al.
        Cancer statistics, 2021.
        CA Cancer J. Clin. 2021; 71: 7-33
        • Talhouk A.
        • et al.
        Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer.
        Cancer. 2017; 123: 802-813
        • Sari A.
        • et al.
        Interobserver agreement for mismatch repair protein immunohistochemistry in endometrial and nonserous, nonmucinous ovarian carcinomas.
        Am. J. Surg. Pathol. 2019; 43: 591-600
        • Vermij L.
        • et al.
        Incorporation of molecular characteristics into endometrial cancer management.
        Histopathology. 2020; 76: 52-63
        • León-Castillo A.
        • et al.
        Molecular classification of the PORTEC-3 trial for high-risk endometrial Cancer: impact on prognosis and benefit from adjuvant therapy.
        J. Clin. Oncol. 2020; 38: 3388-3397
        • Network N.C.C.
        Uterine Neoplasms v1.
        (cited 2022; Available from)
        • Colombo N.
        • et al.
        Endometrial cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
        Ann. Oncol. 2013; 24 (p. vi33-8)
        • Concin N.
        • et al.
        ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma.
        Int. J. Gynecol. Cancer. 2021; 31: 12-39
        • Miller D.S.
        • et al.
        Carboplatin and paclitaxel for advanced endometrial Cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology/GOG0209).
        J. Clin. Oncol. 2020; 38: 3841-3850
        • Fleming G.F.
        Second-line therapy for endometrial Cancer: the need for better options.
        J. Clin. Oncol. 2015; 33: 3535-3540
        • Lincoln S.
        • et al.
        Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study.
        Gynecol. Oncol. 2003; 88: 277-281
        • Garcia A.A.
        • et al.
        A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the gynecologic oncology group.
        Gynecol. Oncol. 2008; 111: 22-26
        • Dizon D.S.
        • et al.
        Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P.
        J. Clin. Oncol. 2009; 27: 3104-3108
        • Di Legge A.
        • et al.
        Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer.
        Int. J. Gynecol. Cancer. 2011; 21: 1446-1451
        • Makker V.
        • et al.
        Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.
        Int. J. Gynecol. Cancer. 2013; 23: 929-934
        • Muggia F.M.
        • et al.
        Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a gynecologic oncology group study.
        J. Clin. Oncol. 2002; 20: 2360-2364
        • Fracasso P.M.
        • et al.
        Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study.
        Gynecol. Oncol. 2006; 103: 523-526
        • Souza R.P.
        • et al.
        Platinum rechallenge in second-line treatment for endometrial carcinoma.
        EJGO. 2019; 40: 963-969
        • Rubinstein M.
        • et al.
        Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: a retrospective study of the memorial Sloan Kettering Cancer center experience.
        Gynecol Oncol Rep. 2019; 28: 120-123
        • Nagao S.
        • et al.
        Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/intergroup study.
        Gynecol. Oncol. 2013; 131: 567-573
        • Campos S.M.
        • D. C.
        Treatment of Metastatic Endometrial Cancer.
        Aug 19. 2022
        • Moore K.N.
        • et al.
        Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?.
        Cancer. 2010; 116: 5407-5414
        • Ueda Y.
        • et al.
        Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin.
        Cancer Chemother. Pharmacol. 2011; 67: 829-835
        • Nagao S.
        • et al.
        What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/intergroup study.
        Cancer Chemother. Pharmacol. 2015; 76: 335-342
        • Colombo N.
        • et al.
        ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease††These consensus statements were developed by the European Society for Medical Oncology (ESMO) and the European Society of Gynaecological Oncology (ESGO) and are published jointly in the Annals of Oncology and the International Journal of Gynecological Cancer. The two societies nominated participants who attended the consensus conference and co-authored the final manuscript.
        Annals of Oncology. 2019; 30: 672-705
        • Marabelle A.
        • et al.
        Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
        Lancet Oncol. 2020; 21: 1353-1365
        • Makker V.
        • et al.
        Lenvatinib plus Pembrolizumab in patients with advanced endometrial Cancer.
        J. Clin. Oncol. 2020; 38: 2981-2992
        • Makker V.
        • et al.
        Lenvatinib plus Pembrolizumab for advanced endometrial Cancer.
        N. Engl. J. Med. 2022; 386: 437-448
        • Asghar U.
        • et al.
        The history and future of targeting cyclin-dependent kinases in cancer therapy.
        Nat. Rev. Drug Discov. 2015; 14: 130-146
        • Mirza M.
        • et al.
        LBA28 a randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO/ENGOT-EN3 trial.
        Ann. Oncol. 2020; 31: S1160
        • Konstantinopoulos P.A.
        • E. L.
        • Xiong N.
        • et al.
        Phase 2, two-stage study of letrozole and abemaciclib in estrogen receptor (ER) positive recurrent or metastatic endometrial cancer (EC).
        in: 2022 SGO Annual Meeting on Women’s Cancer. Phoenix, AZ2022
        • Colon-Otero G.
        • et al.
        Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers.
        ESMO Open. 2020; 5e000926
        • Ashley C.W.
        • et al.
        Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
        Gynecol. Oncol. 2019; 152: 11-19
        • de Jonge M.M.
        • et al.
        Frequent homologous recombination deficiency in high-grade endometrial carcinomas.
        Clin. Cancer Res. 2019; 25: 1087-1097
        • Jönsson J.-M.
        • et al.
        Homologous recombination repair mechanisms in serous endometrial Cancer.
        Cancers. 2021; 13: 254
        • Konstantinopoulos P.A.
        • et al.
        Evaluation of treatment with Talazoparib and Avelumab in patients with recurrent mismatch repair proficient endometrial Cancer.
        JAMA Oncol. 2022; 8: 1317-1322
        • Meng X.
        • et al.
        Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.
        Gynecol. Oncol. 2013; 128: 461-469
        • Liu J.F.
        • et al.
        Phase II study of the WEE1 inhibitor Adavosertib in recurrent uterine serous carcinoma.
        J. Clin. Oncol. 2021; 39: 1531-1539
        • Ross D.S.
        • et al.
        Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas.
        Mod. Pathol. 2022; 35: 962-971
        • Fader A.N.
        • et al.
        Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-Trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2/neu.
        J. Clin. Oncol. 2018; 36: 2044-2051
        • Fader A.N.
        • et al.
        Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-Trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2/Neu (NCT01367002): updated overall survival analysis.
        Clin. Cancer Res. 2020; 26: 3928-3935
        • Hasegawa K.
        • et al.
        813P efficacy and safety of trastuzumab deruxtecan in HER2-expressing uterine carcinosarcoma (STATICE trial, NCCH1615): a multicenter, phase II clinical trial.
        Ann. Oncol. 2021; 32: S767
        • Lissoni A.
        • et al.
        Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer.
        Ann. Oncol. 1996; 7: 861-863
        • Homesley H.D.
        • et al.
        A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer.
        Int. J. Clin. Oncol. 2008; 13: 62-65
        • Thigpen J.T.
        • et al.
        A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study.
        J. Clin. Oncol. 1994; 12: 1408-1414
        • Moreira E.
        • et al.
        Efficacy of doxorubicin after progression on carboplatin and paclitaxel in advanced or recurrent endometrial cancer: a retrospective analysis of patients treated at the Brazilian National Cancer Institute (INCA).
        Med. Oncol. 2018; 35: 20
        • Homesley H.D.
        • et al.
        Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a gynecologic oncology group study.
        Gynecol. Oncol. 2005; 98: 294-298
        • Sutton G.P.
        • et al.
        Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium.
        Cancer. 1994; 73: 1453-1455
        • Miller D.S.
        • et al.
        Phase II evaluation of topotecan in carcinosarcoma of the uterus: a gynecologic oncology group study.
        Gynecol. Oncol. 2005; 98: 217-221
        • McMeekin S.
        • et al.
        Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.
        Gynecol. Oncol. 2015; 138: 18-23
        • Miller D.S.
        • et al.
        A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the gynecologic oncology.
        Gynecol. Oncol. 2009; 115: 443-446
        • Tait D.L.
        • et al.
        A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.
        Gynecol. Oncol. 2011; 121: 118-121
        • Post C.C.B.
        • et al.
        Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
        Gynecol. Oncol. 2022; 165: 223-229
        • Madariaga A.
        • et al.
        Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.
        J. Clin. Oncol. 2021; 39: 5574